A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
B-Cell Targeted Carfilzomib Desensitization
- Status
- UNKNOWN
- Phase
- PHASE1
Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
- Status
- COMPLETED
- Phase
- PHASE3
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE3
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
- Status
- COMPLETED
- Phase
- PHASE1
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
- Status
- COMPLETED
- Phase
- PHASE3
BNHL-2015 for Children or Adolescents in China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Brentuximab for Newly Diagnosed Hodgkin Disease
- Status
- COMPLETED
- Phase
- PHASE2